Selection of extreme phenotypes: The role of clinical observation in translational research

Clinical and Translational Oncology

Volumn 12, Issue 3, 2010, Pages 174-180

  Pérez Gracia, José Luis ^a   Gúrpide, Alfonso ^a   Ruiz Ilundain, María Gloria ^b   Alegría, Carlos Alfaro ^c   Colomer, Ramon ^d   García Foncillas, Jesús ^a   Melero Bermejo, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Universidad Pública de Navarra   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Cancer genetics; Extreme phenotype selection; Familial cancer syndromes; Long term cancer survivors; Protective genetic alterations; Single nucleotide polymorphisms

Indexed keywords

CARCINOGEN; CHEMOKINE RECEPTOR CCR5; FIBRONECTIN; PROTEIN MEN 1; PROTEIN P53; SUNITINIB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER RESEARCH; CANCER RISK; CLINICAL OBSERVATION; CLINICAL RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CARCINOMA; MELANOMA; METHODOLOGY; NONHUMAN; PATIENT SELECTION; PHENOTYPE; REMISSION; REVIEW; SMOKING; TREATMENT RESPONSE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PHENOTYPE; PROGNOSIS; RISK FACTORS; TRANSLATIONAL RESEARCH;

EID: 77952221539     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0487-7     Document Type: Review

References (70)

1. International HapMap Consortium 2005 A haplotype map of the human genome Nature 437 1299 1320 10.1038/nature04226 1:CAS:528:DC%2BD2MXhtFCrur3F (Pubitemid 41568671)
2. N. Freimer C. Sabatti 2003 The human phenome project Nat Genet 34 15 21 10.1038/ng0503-15 12721547 1:CAS:528:DC%2BD3sXjt1Onsbk%3D (Pubitemid 36548781)
3. K.M. Zbuk C. Eng 2007 Cancer phenomics: RET and PTEN as illustrative models Nat Rev Cancer 7 35 45 10.1038/nrc2037 17167516 1:CAS:528: DC%2BD28XhtlCht7nE (Pubitemid 46020845)
4. L. Fernandez-Ricaud J. Warringer E. Ericson, et al. 2007 PROPHECY: a yeast phenome database, update 2006 Nucleic Acids Res 35 D463 467 10.1093/nar/gkl1029 17148481 1:CAS:528:DC%2BD2sXivFGisA%3D%3D (Pubitemid 46056251)
5. S.C. Grubb T.P. Maddatu C.J. Bult M.A. Bogue 2009 Mouse phenome database Nucleic Acids Res 37 D720 730 10.1093/nar/gkn778 18987003 1:CAS:528: DC%2BD1cXhsFejt7jM
6. N. de la Cruz S. Bromberg D. Pasko, et al. 2005 The Rat Genome Database (RGD): developments towards a phenome database Nucleic Acids Res 33 D485 491 10.1093/nar/gki050 15608243 1:CAS:528:DC%2BD2MXisVCitQ%3D%3D (Pubitemid 40207920)
7. E. Singer 2005 "Phenome" project set to pin down subgroups of autism Nat Med 11 583 10.1038/nm0605-583a 15937456 1:CAS:528: DC%2BD2MXkslOltb8%3D
8. P. Groth N. Pavlova I. Kalev, et al. 2007 PhenomicDB: a new cross-species genotype/phenotype resource Nucleic Acids Res 35 D696 699 10.1093/nar/gkl662 16982638 1:CAS:528:DC%2BD2sXivFGhsw%3D%3D (Pubitemid 46056294)
9. P.G. Johnston E.R. Fisher H.E. Rockette, et al. 1994 The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer J Clin Oncol 12 2640 2647 7989939 1:STN:280:DyaK2M%2FotFyjtw%3D%3D
10. A.A. Alizadeh M.B. Eisen R.E. Davis, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 10.1038/35000501 10676951 1:CAS:528:DC%2BD3cXht1Shtrg%3D (Pubitemid 30082188)
11. L.J. van' t Veer H. Dai M.J. van de Vijver, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a (Pubitemid 34130608)
12. H.M. Colhoun P.M. McKeigue G. Davey Smith 2003 Problems of reporting genetic associations with complex outcomes Lancet 361 865 872 10.1016/S0140-6736(03)12715-8 12642066 (Pubitemid 36331853)
13. Editor (1999) Freely associating. Nat Genet 22:1-2
14. J. Little J.P. Higgins J.P. Ioannidis, et al. 2009 STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement PLoS Med 6 e22 10.1371/journal.pmed.1000022 19192942
15. G. Gambaro F. Anglani A. D'Angelo 2000 Association studies of genetic polymorphisms and complex disease Lancet 355 308 311 10.1016/S0140-6736(99) 07202-5 10675088 1:CAS:528:DC%2BD3cXhtlCgtr8%3D (Pubitemid 30068531)
16. D.W. Nebert 2000 Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics Eur J Pharmacol 410 107 120 10.1016/S0014-2999(00)00809-8 11134663 1:CAS:528:DC%2BD3cXovFKjtbk%3D (Pubitemid 32008137)
17. J.L. Perez-Gracia M.G. Ruiz-Ilundain 2001 Cancer protective mutations: looking for the needle in the haystack Clin Transl Oncol 3 169 171
18. J.L. Perez-Gracia M. Gloria Ruiz-Ilundain I. Garcia-Ribas E. Maria Carrasco 2002 The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research Cancer 95 1605 1610 10.1002/cncr.10877 12237932
19. J.K. Reichardt R. Mehrian-Shai 2009 The future of the human SNP identification: which individuals to sequence? Proc Natl Acad Sci U S A 106 E50 10.1073/pnas.0903681106 19416875 1:CAS:528:DC%2BD1MXltFKhtro%3D
20. D.W. Lin M. Porter B. Montgomery 2009 Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study Cancer 115 2863 2871 10.1002/cncr.24324 19466697
21. Online Mendelian Inheritance in Man, OMIM™. Available at http://www.ncbi.nlm.nih.gov/omim/
22. J. Erdheim 1903 Zur normalen und pathologischen Histologie der glandula Thyroidea, Parathyroidea und Hypophysis Beitr Pathol Anat 33 1 234
23. P. Rossier M. Dressler 1939 Familiare Erkrangung innersekretorischer drusen kombiniert mit Ulcuskrankheit Schweiz Med Wochenschr 69 985 990
24. J.R. Schmid A. Labhart P.H. Rossier 1961 Relationship of multiple endocrine adenomas to the syndrome of ulcerogenic islet cell adenomas (Zollinger-Ellison). Occurrence of both syndromes in one family Am J Med 31 343 353 10.1016/0002-9343(61)90123-1 13747921 1:STN:280:DyaF3c%2FmslKgug%3D%3D
25. C. Larsson B. Skogseid K. Oberg, et al. 1988 Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma Nature 332 85 87 10.1038/332085a0 2894610 1:STN:280:DyaL1c7ls12iuw%3D%3D (Pubitemid 18083554)
26. S.C. Chandrasekharappa S.C. Guru P. Manickam, et al. 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1 Science 276 404 407 10.1126/science.276.5311.404 9103196 1:CAS:528:DyaK2sXis1Khu7k%3D (Pubitemid 27180699)
27. J.M. Hall M.K. Lee B. Newman, et al. 1990 Linkage of early-onset familial breast cancer to chromosome 17q21 Science 250 1684 1689 10.1126/science.2270482 2270482 1:STN:280:DyaK3M7gt1GnsA%3D%3D
28. R.W. Miller 1968 Deaths from childhood cancer in sibs N Engl J Med 279 122 126 5655197 1:STN:280:DyaF1c3nvFOlsw%3D%3D
29. F.P. Li J.F. Fraumeni Jr 1969 Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome J Natl Cancer Inst 43 1365 1373 5396222 1:STN:280:DyaE3M%2FgsVentw%3D%3D
30. D. Malkin F.P. Li L.C. Strong, et al. 1990 Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 250 1233 1238 10.1126/science.1978757 1978757 1:CAS:528:DyaK3MXjslSisw%3D%3D
31. M. Tuchman J.S. Stoeckeler D.T. Kiang, et al. 1985 Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity N Engl J Med 313 245 249 2989687 1:STN:280:DyaL2M3ktVCmsQ%3D%3D
32. R.B. Diasio T.L. Beavers J.T. Carpenter 1988 Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity J Clin Invest 81 47 51 10.1172/JCI113308 3335642 1:STN:280:DyaL1c%2Fosl2jug%3D%3D
33. A.B. Van Kuilenburg P. Vreken L.V. Beex, et al. 1997 Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity Eur J Cancer 33 2258 2264 10.1016/S0959-8049(97)00261-X 9470816 (Pubitemid 28123420)
34. J.G. Paez P.A. Janne J.C. Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 10.1126/science.1099314 15118125 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
35. T.J. Lynch D.W. Bell R. Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 10.1056/NEJMoa040938 15118073 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
36. R.S. Herbst D. Prager R. Hermann, et al. 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892 5899 10.1200/JCO.2005.02.840 16043829 1:CAS:528:DC%2BD2MXhtVKgtbzN
37. U. Gatzemeier A. Pluzanska A. Szczesna, et al. 2007 Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced nonsmall-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 1545 1552 10.1200/JCO.2005.05.1474 17442998 1:CAS:528: DC%2BD2sXlsVynur4%3D (Pubitemid 46733081)
38. G. Giaccone R.S. Herbst C. Manegold, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 777 784 10.1200/JCO.2004.08.001 14990632 1:CAS:528:DC%2BD2cXpsVKjur4%3D (Pubitemid 41103588)
39. R.S. Herbst G. Giaccone J.H. Schiller, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 785 794 10.1200/JCO.2004.07.215 14990633 1:CAS:528:DC%2BD2cXpsVKjur0%3D (Pubitemid 41103589)
40. G. Zhang D.W. Nebert R. Chakraborty L. Jin 2006 Statistical power of association using the extreme discordant phenotype design Pharmacogenet Genomics 16 401 413 10.1097/01.fpc.0000204995.99429.0f 16708049 1:CAS:528: DC%2BD28XkslKrt78%3D (Pubitemid 43804798)
41. E. Silberstein S. Walfisch L. Lupu I. Sztarkier 2000 Twelve-year survival after the diagnosis of locally advanced carcinoma of the pancreas: a case report J Surg Oncol 75 142 145 10.1002/1096-9098(200010)75:2<142::AID- JSO13>3.0.CO;2-8 11064396 1:STN:280:DC%2BD3M%2FjsVKgsQ%3D%3D
42. G.P. Spinelli A. Zullo A. Romiti, et al. 2006 Longterm survival in metastatic pancreatic cancer. A case report and review of the literature JOP 7 486 491 16998247
43. M. Miyaji K. Ogoshi Y. Kajiura, et al. 1996 [A case of advanced gastric cancer with liver metastasis with no recurrence and long survival] Gan To Kagaku Ryoho 23 915 918 8678542 1:STN:280:DyaK283ot1Kitg%3D%3D
44. N. Shibata M. Tamai K. Ikeda 1995 [Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy] Gan To Kagaku Ryoho 22 119 122 7826066 1:STN:280:DyaK2M7is1Kiuw%3D%3D
45. T. Fukasawa T. Shoji H. Gotoh K. Taniwaka 2006 [A long-term survivor with stage IV gastric cancer due to postoperative weekly paclitaxel and 5'-DFUR combination therapy] Gan To Kagaku Ryoho 33 235 238 16484863
46. T. Wada T. Iwanaga H. Koyama, et al. 1988 [A case report of long-term survival in advanced gastric cancer with multiple liver metastases treated with mitomycin C and tegafur therapy after palliative gastrectomy] Gan To Kagaku Ryoho 15 353 356 2449135 1:STN:280:DyaL1c7jt12mtA%3D%3D
47. M. Mukai N. Tokunaga S. Yasuda, et al. 2000 Long-term survival after immunochemotherapy for juvenile colon cancer with peritoneal dissemination: a case report Oncol Rep 7 1343 1347 11032941 1:STN:280:DC%2BD3cvovFGhsA%3D%3D
48. T. Seto M. Seto K. Ono, et al. 2000 [A long-term survivor of extensive-stage small cell lung cancer] Gan To Kagaku Ryoho 27 135 138 10660747 1:STN:280:DC%2BD3c7is1Grtg%3D%3D
49. J.W. Mall A.W. Philipp W. Mall C. Pollmann 2002 Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy Angiogenesis 5 11 13 10.1023/A:1021546630577 12549855 1:CAS:528:DC%2BD38Xptl2qu7s%3D (Pubitemid 36082829)
50. Y. Izumi M. Mukai K. Kikuchi K. Kobayashi 2006 Long-term survival after incomplete resection of immunohistochemically diagnosed T0N1 lung cancer: report of a case Surg Today 36 270 273 10.1007/s00595-005-3147-8 16493539 (Pubitemid 43288723)
51. M.P. Mac Manus J.P. Matthews M. Wada, et al. 2006 Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer Cancer 106 1110 1116 10.1002/cncr.21704 16432830
52. J.P. Dutcher P.H. Wiernik 1984 Long-term survival of a patient with multiple myeloma: a cure? A case report Cancer 53 2069 2072 10.1002/1097- 0142(19840515)53:10<2069::AID-CNCR2820531011>3.0.CO;2-L 6704893 1:STN:280:DyaL2c7ls1SktQ%3D%3D
53. G.V. Yamshchikov D.W. Mullins C.C. Chang, et al. 2005 Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma J Immunol 174 6863 6871 15905528 1:CAS:528:DC%2BD2MXkt1Omt7s%3D
54. F.A. Le Gal V.M. Widmer V. Dutoit, et al. 2007 Tissue homing and persistence of defined antigenspecific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors J Invest Dermatol 127 622 629 10.1038/sj.jid. 5700580 17039243 1:CAS:528:DC%2BD2sXhs1Crtr4%3D
55. G. Yamshchikov L. Thompson W.G. Ross, et al. 2001 Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations Clin Cancer Res 7 909s 916s 11300491 1:CAS:528:DC%2BD3MXjtFWksb4%3D
56. G.P. Dunn L.J. Old R.D. Schreiber 2004 The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 137 148 10.1016/j.immuni.2004. 07.017 15308095 1:CAS:528:DC%2BD2cXnsVKltrY%3D (Pubitemid 39094044)
57. J.L. Perez-Gracia C. Prior F. Guillen-Grima, et al. 2009 Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array Br J Cancer 101 1876 1883 10.1038/sj.bjc.6605409 19904265 1:CAS:528:DC%2BD1MXhsVOhtLjK
58. M. Sabatino S. Kim-Schulze M.C. Panelli, et al. 2009 Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy J Clin Oncol 27 2645 2652 10.1200/JCO.2008.19.1106 19364969 1:CAS:528:DC%2BD1MXnslWit7k%3D
59. R. Liu W.A. Paxton S. Choe, et al. 1996 Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 367 377 10.1016/S0092-8674(00)80110-5 8756719 1:CAS:528:DyaK28XltVSks7k%3D (Pubitemid 26272077)
60. C. Quillent E. Oberlin J. Braun, et al. 1998 HIV-1- resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene Lancet 351 14 18 10.1016/S0140-6736(97)09185-X 9433423 1:CAS:528:DyaK1cXmt12rsQ%3D%3D (Pubitemid 28020160)
61. S. Rowland-Jones J. Sutton K. Ariyoshi, et al. 1995 HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women Nat Med 1 59 64 10.1038/nm0195-59 7584954
62. I. Garcia-Cao M. Garcia-Cao J. Martin-Caballero, et al. 2002 "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally EMBO J 21 6225 6235 10.1093/emboj/cdf595 12426394 1:CAS:528: DC%2BD38XptFOrsbs%3D (Pubitemid 35415339)
63. Q. Yu Y. Geng P. Sicinski 2001 Specific protection against breast cancers by cyclin D1 ablation Nature 411 1017 1021 10.1038/35082500 11429595 1:CAS:528:DC%2BD3MXltVClu7g%3D (Pubitemid 32612319)
64. Z. Cui M.C. Willingham A.M. Hicks, et al. 2003 Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice Proc Natl Acad Sci U S A 100 6682 6687 10.1073/pnas.1031601100 12724523 1:CAS:528:DC%2BD3sXktlygs7Y%3D (Pubitemid 36666641)
65. W.C. Black H.G. Welch 1993 Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy N Engl J Med 328 1237 1243 10.1056/NEJM199304293281706 8464435 1:STN:280:DyaK3s3hvVKluw%3D%3D (Pubitemid 23115703)
66. E.V. Belogubova A.V. Togo M.B. Karpova, et al. 2004 A novel approach for assessment of cancer predisposing roles of GSTM1 and GSTT1 genes: use of putatively cancer resistant elderly tumor-free smokers as the referents Lung Cancer 43 259 266 10.1016/j.lungcan.2003.08.019 15165083 (Pubitemid 38224145)
67. E.V. Belogubova E. Kuligina A.V. Togo, et al. 2005 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility Cancer Lett 221 177 183 10.1016/j.canlet.2004.11.008 15808403 1:CAS:528:DC%2BD2MXivV2gsbo%3D (Pubitemid 40460404)
68. E.V. Belogubova Y.M. Ulibina I.K. Suvorova, et al. 2006 Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects J Cancer Res Clin Oncol 132 327 331 10.1007/s00432-005-0071-7 16416283 1:CAS:528:DC%2BD28XhvVaqtLw%3D
69. E.V. Belogubova A.V. Togo T.V. Kondratieva, et al. 2000 GSTM1 genotypes in elderly tumour-free smokers and non-smokers Lung Cancer 29 189 195 10.1016/S0169-5002(00)00120-3 10996421 1:STN:280:DC%2BD3M%2FhsVyjtg%3D%3D
70. F.S. Collins E.D. Green A.E. Guttmacher M.S. Guyer 2003 A vision for the future of genomics research Nature 422 835 847 10.1038/nature01626 12695777 1:CAS:528:DC%2BD3sXjtFCitbc%3D (Pubitemid 36520032)